Drug Trial Radar · NCT04570423
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
May 20, 2021
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Spectrum Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Conditions
- Solid Tumors
- Lymphoma
Interventions
EflapegrastimDrug
Eflapegrastim supplied in prefilled, single-use syringes for SC injection.
ChemotherapyDrug
Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care per the Primary Care physician's treatment plan.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug to 35 days after the last dose of the study drug (Up to approximately 16 months)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
New York Medical College
Valhalla, New York · Terminated
Carolinas Medical Center/ Levine Children's Hospital
Charlotte, North Carolina · Terminated
Levine Children's Health
Charlotte, North Carolina · Terminated
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
UT MD Anderson Cancer Center
Houston, Texas · Terminated
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.